Women with polyendocrine metabolic ovarian syndrome (PMOS) represent a particularly challenging patient population, characterized by the convergence of reproductive dysfunction, obesity, insulin resistance, and chronic inflammation. The emergence of glucagon-like peptide-1 receptor agonists (GLP-1RAs) offers a transfor...
Pawel Kordowitzki, A. Joham, C. Rosen· Cell Metabolism· 0 citations
In unselected populations, the majority of women with PCOS exhibit a normal BMI, in contrast to clinic-based cohorts, where obesity is markedly overrepresented, which indicates that longitudinal, population-based studies integrating multi-omic data are essential for unraveling BMI-related heterogeneity.
A. Bizuneh, C. Tay, Arul Earnest et al.· European Journal of Endocrin...· 0 citations
Recognizing PMOS as an early-life marker of cardiometabolic disease highlights opportunities for earlier diagnosis, prevention, and individualized risk stratification, supporting integrated, patient-centered care across the life course.
M. Forslund, J. Melin, A. Joham et al.· Journal of Internal Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.